2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 486

The Electrophysiologic and Sonographic Evaluation of Peripheral Nerves in Rheumatoid Arthritis Patients
Abstract Number: 248

The Emotional Quotient in Fibromyalgia Patients Is Similar to Rheumatic Disease Controls
Abstract Number: 2069

The Epigenetic Regulator Sirtuin-1 Modulates T-Helper 17 Cell Differentiation in Axial Spondyloarthritis
Abstract Number: 1195

The Evaluation of the Small Enthesis of the Hands By Ultrasound: A Study on Healthy Subjects
Abstract Number: 1911

The Expanding Clinical Spectrum of Patients with Deficiency of Adenosine Deaminase 2 (DADA2)
Abstract Number: 1100

The Frequencies and Molecular Profiles of CD16+ Monocyte Subsets in Patients with Systemic Lupus Erythematosus, Primary Antiphospholipid Syndrome, and Antiphospholipid Syndrome with Lupus, Identify Specific Clinical Features of These Diseases
Abstract Number: 451

The Frequency of Neuropathic Pain in Patients with Low Back Pain and the Relationship with Demographic Characteristics: A Cross-Sectional Study
Abstract Number: 159

The Frequency of Screening and Prevalence of Antiphospholipid Antibodies in the General Population
Abstract Number: 2414

The Global Antiphospholipid Syndrome Score in Women with Systemic Lupus Erythematosus and Adverse Pregnancy Outcomes
Abstract Number: 178

The Impact of a Novel Immune Related Adverse Event Tumor Board on Interprofessional Clinical Confidence and Collaboration
Abstract Number: 330

The IMPACT of a Referral Algorithm for Axial Spondyloarthritis: Four Month Follow-up in Patient Reported Outcomes
Abstract Number: 2397

The Impact of Adalimumab on Growth in Patients with Pediatric Enthesitis-Related Arthritis
Abstract Number: 2425

The Impact of Biologic Treatment for Rheumatoid Arthritis Patients Who Hope to Conceive
Abstract Number: 2340

The Impact of Chronic Glucocorticoid Use Amongst Patients with Rheumatoid Arthritis: A Qualitative Study
Abstract Number: 557

The Impact of Comedication with Conventional Synthetic Dmards on Drug Retention and Clinical Effectiveness of Tofacitinib, Anti–Tumor Necrosis Factor Therapy and Biologics with an Alternative Mode of Action in Patients with Rheumatoid Arthritis. a Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].